News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Subscribe To Our Newsletter & Stay Updated
